INTERMITTENT EPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROME: A Double-blind Controlled Trial

Abstract Two groups of outpatients (7 in each group) with Raynaud's syndrome, matched for severity of illness, were randomly allocated to receive at weekly intervals for three weeks either a 5 h intravenous infusion of buffer or epoprostenol (prostacyclin, PGI 2 ) in buffer (7·5 ng/kg/min after the first hour). PGI 2 reduced the frequency and duration of ischaemic attacks (both p